Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
Woo SJ, Veith M, Hamouz J, Ernest J, Zalewski D, Studnicka J, Vajas A, Papp A, Gabor V, Luu J, Matuskova V, Yoon YH, Pregun T, Kim T, Shin D, Bressler NM. Woo SJ, et al. Among authors: matuskova v. JAMA Ophthalmol. 2021 Jan 1;139(1):68-76. doi: 10.1001/jamaophthalmol.2020.5053. JAMA Ophthalmol. 2021. PMID: 33211076 Free PMC article. Clinical Trial.
Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes.
Bressler NM, Veith M, Hamouz J, Ernest J, Zalewski D, Studnička J, Vajas A, Papp A, Vogt G, Luu J, Matuskova V, Yoon YH, Pregun T, Kim T, Shin D, Oh I, Jeong H, Kim MY, Woo SJ. Bressler NM, et al. Among authors: matuskova v. Br J Ophthalmol. 2023 Mar;107(3):384-391. doi: 10.1136/bjophthalmol-2021-319637. Epub 2021 Oct 16. Br J Ophthalmol. 2023. PMID: 34656987 Free PMC article. Clinical Trial.
CD36 gene is associated with intraocular pressure elevation after intravitreal application of anti-VEGF agents in patients with age-related macular degeneration: Implications for the safety of the therapy.
Matušková V, Balcar VJ, Khan NA, Bonczek O, Ewerlingová L, Zeman T, Kolář P, Vysloužilová D, Vlková E, Šerý O. Matušková V, et al. Ophthalmic Genet. 2018 Jan-Feb;39(1):4-10. doi: 10.1080/13816810.2017.1326508. Epub 2017 May 30. Ophthalmic Genet. 2018. PMID: 28557591
45 results